Med Ad Views Episode 07: Med Ad News 2026 Marketer on the Rise Recipient Dipa Sapre

Why It Matters

Sapre’s recognition highlights the growing importance of obesity therapeutics and underscores the need for diverse leadership in pharma marketing, influencing how brands engage clinicians and patients.

Key Takeaways

• Novo Nordisk’s obesity brand earned Best Launch Campaign nomination
• Sapre stresses data‑driven digital tools for HCP engagement
• Mentorship and inclusion are pivotal for next‑gen pharma marketers
• Award signals rising strategic focus on obesity therapeutics

Pulse Analysis

The 2026 Marketer on the Rise Manny Award shines a spotlight on emerging leaders who are redefining pharmaceutical marketing. Dipa Sapre’s win reflects Novo Nordisk’s aggressive push into obesity, a therapeutic segment projected to exceed $10 billion in U.S. sales by 2030. Her experience across Johnson & Johnson, BMS, and Lexicon equips her with a cross‑company perspective on brand building, from early‑stage pipeline positioning to post‑launch optimization. By leveraging real‑time analytics and omnichannel platforms, Sapre illustrates how modern HCP strategy blends clinical evidence with personalized digital outreach, a model other pharma firms are rapidly adopting.

Beyond tactics, Sapre’s candid discussion on diversity underscores a broader industry shift. Women and BIPOC professionals remain underrepresented in senior marketing roles, yet research shows diverse teams drive higher revenue growth. Sapre’s mentorship initiatives aim to close that gap, fostering a pipeline of talent that can navigate complex therapeutic landscapes and regulatory environments. Her advice—prioritize authentic relationships, seek data‑backed insights, and champion inclusive leadership—resonates with companies striving to modernize culture while maintaining compliance.

Looking ahead, the obesity market’s momentum will demand innovative launch strategies that balance scientific rigor with patient‑centric storytelling. Sapre anticipates next‑generation tools such as AI‑driven audience segmentation and virtual reality educational experiences to deepen HCP engagement. As payers tighten reimbursement criteria, marketers must demonstrate value through outcomes data and real‑world evidence. Sapre’s trajectory and the Manny Award signal that the future of pharma marketing will be led by leaders who blend strategic acumen, technological fluency, and a commitment to inclusive growth.